Consun Pharmaceutical Group is forecast to grow earnings and revenue by 11.8% and 11.8% per annum respectively. EPS is expected to grow by 11.9% per annum. Return on equity is forecast to be 24.4% in 3 years.
Key information
11.8%
Earnings growth rate
11.88%
EPS growth rate
Pharmaceuticals earnings growth
14.4%
Revenue growth rate
11.8%
Future return on equity
24.40%
Analyst coverage
Low
Last updated
30 Mar 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
OTCPK:CPHG.F - Analysts future estimates and past financials data (CNY Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
4,918
1,546
1,234
N/A
2
12/31/2027
4,301
1,388
1,046
N/A
3
12/31/2026
3,883
1,244
912
N/A
2
12/31/2025
3,417
1,078
N/A
N/A
N/A
9/30/2025
3,342
1,044
N/A
N/A
N/A
6/30/2025
3,267
1,009
1,143
1,229
N/A
3/31/2025
3,117
960
1,061
1,158
N/A
12/31/2024
2,967
910
978
1,087
N/A
9/30/2024
2,853
873
905
1,001
N/A
6/30/2024
2,739
836
833
915
N/A
3/31/2024
2,665
810
800
867
N/A
12/31/2023
2,590
785
766
819
N/A
9/30/2023
2,528
759
797
844
N/A
6/30/2023
2,466
734
828
869
N/A
3/31/2023
2,403
708
862
908
N/A
12/31/2022
2,340
683
896
948
N/A
9/30/2022
2,246
660
836
906
N/A
6/30/2022
2,152
636
776
865
N/A
3/31/2022
2,098
613
701
795
N/A
12/31/2021
2,045
590
627
726
N/A
9/30/2021
1,959
565
655
731
N/A
6/30/2021
1,874
541
683
737
N/A
3/31/2021
1,813
520
748
802
N/A
12/31/2020
1,753
499
813
867
N/A
9/30/2020
1,653
269
639
717
N/A
6/30/2020
1,553
39
465
567
N/A
3/31/2020
1,641
60
334
475
N/A
12/31/2019
1,728
80
203
383
N/A
9/30/2019
1,822
288
N/A
442
N/A
6/30/2019
1,916
496
N/A
501
N/A
3/31/2019
1,880
481
N/A
628
N/A
12/31/2018
1,844
465
N/A
754
N/A
9/30/2018
1,802
448
N/A
662
N/A
6/30/2018
1,760
430
N/A
570
N/A
3/31/2018
1,710
413
N/A
411
N/A
12/31/2017
1,660
396
N/A
252
N/A
9/30/2017
1,601
372
N/A
323
N/A
6/30/2017
1,541
347
N/A
393
N/A
3/31/2017
1,382
327
N/A
421
N/A
12/31/2016
1,223
308
N/A
449
N/A
9/30/2016
1,060
291
N/A
362
N/A
6/30/2016
896
274
N/A
275
N/A
3/31/2016
863
262
N/A
230
N/A
12/31/2015
831
250
N/A
184
N/A
9/30/2015
814
246
N/A
180
N/A
6/30/2015
798
242
N/A
175
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CPHG.F's forecast earnings growth (11.8% per year) is above the savings rate (3.4%).
Earnings vs Market: CPHG.F's earnings (11.8% per year) are forecast to grow slower than the US market (15.5% per year).
High Growth Earnings: CPHG.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: CPHG.F's revenue (11.8% per year) is forecast to grow faster than the US market (10.4% per year).
High Growth Revenue: CPHG.F's revenue (11.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CPHG.F's Return on Equity is forecast to be high in 3 years time (24.4%)
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/04/04 14:31
End of Day Share Price
2026/01/05 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Consun Pharmaceutical Group Limited is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.